Skip to main content
    P

    Praxis Precision Medicines Inc (PRAX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $310.27
    -17.86 (-5.44%)

    Market Cap: $9.17B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Praxis Precision Medicines Inc (PRAX) Earnings: Report Dates and Results

    Updated Nov 9, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Praxis Precision Medicines (PRAX) is expected to report earnings on Feb 17, 2027. In the quarter ended Sep 30, 2026, Praxis Precision Medicines reported EPS of -$3.23, above the -$3.68 estimate. It beat the EPS estimate in 5 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    44%(11/25)
    Avg Surprise
    -8.67%
    Streak
    3 Q

    Upcoming Estimates

    Reports Feb 17, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$4.00
    Range-$5.04 - -$1.05
    23 analysts
    Revenue Consensus
    $633.36K
    RangeN/A
    21 analysts
    Reports May 5, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$3.75
    Range-$5.50 - $1.94
    11 analysts
    EPS Revisions
    3
    2
    30d
    EPS Estimate DriftChange to current
    90d ago-$3.88+3.4%
    60d ago-$3.89+3.6%
    30d ago-$3.90+3.9%
    7d ago-$3.99+6.0%
    Current-$3.75
    Revenue Consensus
    $31.84M
    Range$4.00M - $190.10M
    11 analysts

    Next Report

    PRAX has an expected report date of Feb 17, 2027.

    PRAX Earnings Call

    The latest PRAX earnings call transcript on file is labeled 2026Q2.

    Read the 2026Q2 transcript

    Earnings History

    Of the 25 quarters below that had an estimate, PRAX beat 11 and missed 14. The widest gap in the table came in the quarter ended Dec 31, 2020, when EPS landed 135.14% below the estimate.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$3.23-$3.68-$5.60 - -$2.74+12.23%BeatN/A190 up, 0 downNov 9, 2026N/A
    Jun 30, 2026-$2.87-$3.60-$5.33 - -$3.04+20.28%BeatN/A16N/AAug 6, 2026N/A
    Mar 31, 2026-$3.20-$3.68-$5.23 - -$2.98+13.04%BeatN/A121 up, 4 downMay 7, 2026N/A
    Dec 31, 2025-$3.50-$3.13-$4.16 - -$2.17-11.82%MissN/A141 up, 1 downFeb 19, 2026N/A
    Sep 30, 2025-$3.36-$3.45-$4.06 - -$3.10+2.61%BeatN/A120 up, 1 downNov 5, 2025N/A
    Jun 30, 2025-$3.31-$3.36-$3.96 - -$2.93+1.49%BeatN/A100 up, 1 downAug 4, 2025N/A
    Mar 31, 2025-$3.29-$3.21-$3.69 - -$2.77-2.49%MissN/A91 up, 6 downMay 2, 2025N/A
    Dec 31, 2024-$2.94-$2.82-$3.23 - -$2.41-4.29%MissN/A90 up, 2 downFeb 28, 2025$7.46M
    Sep 30, 2024-$2.75-$1.95-$2.23 - -$1.74-41.03%MissN/A100 up, 0 downNov 6, 2024$302000
    Jun 30, 2024-$1.74-$2.32-$3.24 - -$1.72+25.00%BeatN/A100 up, 0 downAug 13, 2024$357000
    Mar 31, 2024-$2.84-$2.16-$2.24 - -$1.72-31.48%MissN/A70 up, 0 downMay 13, 2024$431000
    Dec 31, 2023-$2.97-$3.18-$3.59 - -$2.99+6.60%BeatN/A61 up, 0 downMar 5, 2024$515000
    Sep 30, 2023-$2.70-$4.89-$7.80 - -$4.05+44.79%BeatN/A61 up, 0 downNov 7, 2023$468000
    Jun 30, 2023-$7.35-$10.60-$11.09 - -$7.65+30.66%BeatN/A50 up, 0 downAug 9, 2023$781000
    Mar 31, 2023-$10.65-$12.80-$13.64 - -$8.70+16.80%BeatN/A40 up, 0 downMay 11, 2023$683000
    Dec 31, 2022-$13.05-$12.03-$16.04 - -$9.60-8.48%MissN/A60 up, 0 downFeb 7, 2023N/A
    Sep 30, 2022-$14.40-$14.01-$17.39 - -$10.34-2.78%MissN/A50 up, 0 downNov 9, 2022N/A
    Jun 30, 2022-$19.80-$19.27N/A-2.75%MissN/AN/A1 up, 0 downAug 8, 2022N/A
    Mar 31, 2022-$1.51-$1.30-$1.41 - -$1.18-16.15%MissN/A61 up, 0 downMay 9, 2022N/A
    Dec 31, 2021-$19.50-$16.05-$17.84 - -$13.94-21.50%MissN/A6N/AFeb 28, 2022N/A
    Sep 30, 2021-$15.00-$13.95-$15.59 - -$12.14-7.53%MissN/A5N/ANov 3, 2021N/A
    Jun 30, 2021-$13.20-$10.12-$11.84 - -$9.45-30.43%MissN/A4N/AAug 16, 2021N/A
    Mar 31, 2021-$10.65-$11.14-$13.64 - -$8.70+4.40%BeatN/A4N/AMay 11, 2021N/A
    Dec 31, 2020-$0.87-$0.37-$0.46 - -$0.29-135.14%MissN/A2N/AMar 17, 2021N/A
    Sep 30, 2020-$7.90-$4.42-$23.99 - -$4.05-78.73%MissN/A3N/AOct 16, 2020N/A
    Jun 30, 2020-$3.90N/AN/AN/AN/AN/AN/AN/ASep 2, 2020N/A
    Last 26 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$13.46, after -$10.27 the year before. It was -$12.67 for the year ended Dec 31, 2020, the oldest of the 6 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$13.46N/A
    Dec 31, 2024-$10.27N/A
    Dec 31, 2023-$23.67N/A
    Dec 31, 2022-$48.76N/A
    Dec 31, 2021-$58.35N/A
    Dec 31, 2020-$12.67N/A

    Earnings Calls

    The 5 most recent earnings calls are listed below; the latest, 2026Q2 for the period ended Jun 30, 2026, runs about 4,900 words across 23 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q2Jun 30, 20264,87423
    2026Q1Mar 31, 20266,67017
    2025Q4Dec 31, 20257,69918
    2025Q2Jun 30, 20256,66014
    2024Q3Sep 30, 20245,80212

    2026Q2 Earnings Call

    Opening remarks

    Daniel Ferry Managing Director, LifeSci Advisors Good morning, and welcome to the Praxis Precision Medicines Second Quarter 2026 Financial Results and Business Update Conference Call. This call is being webcast live and can be accessed on the Investors section of Praxis' website at www.praxismedicines.com. Please note that remarks made during this call may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These may include statements about the company's future expectations and plans, clinical development timelines and financial projections. While these forward-looking statements represent Praxis' views as of today, they should not be relied upon as representing the company's views in the future. Praxis may update these statements in the future, but is not taking on an obligation to do so. Please refer to Praxis' most recent filings with the Securities and Exchange Commission for a discussion of certain risks and uncertainties associated with the company's business. Joining us on today's call are Marcio DeSouza, President and Chief Executive Officer of Praxis; and Tim Kelly, our Chief Financial Officer. After providing updates on our key programs, we'll move to a brief Q&A session where Marcio and Tim will be joined by Steve Petrou, President of Research and Development; and Megan Sniecinski, Chief Operating Officer. With that, it's my pleasure to turn the call over to Marcio. Marcio?

    Marcio DeSouza President and Chief Executive Officer Thank you, Dan. Good morning, everyone. Thank you for joining Praxis Second Quarter 2026 Conference Call. Three months ago, I told you this would be the year Praxis becomes a commercial company. This quarter is the one where that stopped being a plan and started materializing into the organization. We have two NDAs in late-stage review with the FDA with both approvals expected in about six months. It's extremely exciting to bring both ulixacaltamide to ET patients and relutrigine to SCN2A and SCN8A patients. We have commercial leadership in place, a field force for the first launch hires and training and a distribution network established and inventory being built. I want to spend most of my time today on some key regulatory developments and what we have been building. Let me start with ulixacaltamide. Essential tremor affects over 7 million Americans, and there is still no FDA-approved therapy developed specifically to treat the condition. With the potential approval coming up by January next year, ulixacaltamide is poised to change that. Speaking about the NDA review, the FDA completed its mid-cycle communications with us and we are very pleased with the progress and discussions with the agency. In that meeting, the agency identified no efficacy-related significant issues and stated that it does not plan to request an advisory committee meeting. I would characterize the discussion as expected and very forward-looking.

    Frequently Asked Questions About PRAX

    When is Praxis Precision Medicines's next earnings date?

    Praxis Precision Medicines's next earnings report is expected for Feb 17, 2027.

    Did PRAX beat earnings estimates last quarter?

    Yes. Praxis Precision Medicines reported EPS of -$3.23 for the quarter ended Sep 30, 2026, above the -$3.68 estimate, a 12.23% surprise.

    What EPS do analysts expect from PRAX next quarter?

    The consensus EPS estimate for Praxis Precision Medicines for the quarter ending Dec 31, 2026 is -$4.00 from 23 analysts, with estimates from -$5.04 to -$1.05.

    How often does PRAX beat earnings estimates?

    Praxis Precision Medicines beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of +3.88%.